Aim: This study aimed to evaluate the association between admission lactate to albumin ratio (LAR) and in-hospital mortality in critically ill patients hospitalized with acute decompensated heart failure (ADHF).Material sand Methods: This retrospective single-center study included 87 adult patients admitted to a coronary intensive care unit (ICU) with ADHF. LAR was calculated using admission laboratory values. Patients were classified according to in-hospital survival status. Clinical, laboratory, and echocardiographic variables were analyzed to identify predictors of in-hospital mortality. Receiver operating characteristic (ROC) analysis was performed to assess the prognostic performance of the LAR.Results: In-hospital mortality occurred in 29 of 87 patients (33.3%). Median lactate levels were significantly higher in non-survivors compared with survivors (3.47 vs. 2.10 mmol/L, p < 0.001). The LAR was also higher in non-survivors (0.93 vs. 0.59, p = 0.002), while left ventricular ejection fraction (LVEF) was lower (28.2% vs. 36.1%, p = 0.006). In multivariable logistic regression analysis, mechanical ventilation (adjusted OR 80.8, p < 0.001) and LVEF (adjusted OR 0.92 per %, p = 0.016) were independently associated with in-hospital mortality, whereas the LAR was not (p = 0.266). ROC analysis demonstrated fair discrimination for the LAR in predicting mortality (AUC 0.706).Conclusion: Although higher LAR values were associated with mortality in unadjusted analysis, this marker did not provide independent prognostic value beyond established indicators of disease severity in critically ill patients with ADHF.
21 November 2025 in Medical Principles and Practice
Background: Dapagliflozin (DAPA), a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejection fraction (HFrEF). The antiarrhythmic mechanisms of SGLT2 inhibitors are not fully known. Recently, the index of cardiac electrophysiological balance (ICEB) has been posited as a robust indicator for predicting VA risk. ICEB reflects the balance between ventricular depolarization and repolarization. This study was conducted to investigate the effects of DAPA treatment on ICEB in a cohort of patients with HFrEF.Methods: A total of 235 HFrEF patients undergoing DAPA treatment were enrolled in the study. Each participant underwent a comprehensive 12‐lead electrocardiography (ECG) assessment prior to treatment initiation and approximately 6 months posttreatment. ICEB values were compared before and after treatment.Results: The analysis revealed a statistically significant reduction in the QT interval (427.51 ± 13.87 vs. 347.75 ± 11.21 ms, p < 0.001), corrected QT interval (QTc) (458.34 ± 29.71 vs. 393.37 ± 13.21 ms, p < 0.001), T peak‐to‐end (Tp‐e) interval (85.41 ± 3.52 vs. 71.18 ± 3.16 ms, p < 0.001), Tp‐e/QTc ratio (0.186 ± 0.009 vs. 0.180 ± 0.003, p < 0.001), ICEB (4.59 ± 0.65 vs. 3.77 ± 0.15, p < 0.001), following approximately 6 months of DAPA treatment.Conclusion: In addition to ventricular repolarization distribution indices, the regression of the ICEB values after DAPA treatment in patients with HFrEF shows that DAPA treatment improves the balance between ventricular depolarization and repolarization and reduces the risk of VA in these patients.